These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38352847)

  • 61. Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):773-774. PubMed ID: 38894899
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Aug; 15(8):1201-1202. PubMed ID: 39140050
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hetero-tricyclic Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Sep; 14(9):1154-1155. PubMed ID: 37736182
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
    Sabnis RW
    ACS Med Chem Lett; 2024 Feb; 15(2):163-164. PubMed ID: 38352824
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
    Sabnis RW
    ACS Med Chem Lett; 2023 Nov; 14(11):1501-1502. PubMed ID: 37974937
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
    Sabnis RW
    ACS Med Chem Lett; 2023 Oct; 14(10):1318-1319. PubMed ID: 37849545
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel C-Linked Isoquinoline Amides as LRRK2 Inhibitors for Treating Parkinson's Disease.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2023 Jun; 14(6):698-699. PubMed ID: 37312864
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Factor XI Activation Inhibitors for Treating Thromboses, Embolism, Hypercoagulability, or Fibrotic Changes.
    Sabnis RW
    ACS Med Chem Lett; 2022 Oct; 13(10):1548-1549. PubMed ID: 36267132
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
    Mifflin L; Ofengeim D; Yuan J
    Nat Rev Drug Discov; 2020 Aug; 19(8):553-571. PubMed ID: 32669658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
    Sabnis RW
    ACS Med Chem Lett; 2023 Nov; 14(11):1491-1492. PubMed ID: 37974944
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
    Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
    Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Mar; 15(3):342-343. PubMed ID: 38505844
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors.
    Hao Y; Shao H; Qu Z; Li J; Shi Y; Zhang W; Yu J; Fu P; Zhuang C
    Eur J Med Chem; 2022 Jun; 236():114345. PubMed ID: 35398729
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Novel Adenosine Receptor Antagonists for Treating Cancer and Immune-Related Disorders.
    Sabnis RW
    ACS Med Chem Lett; 2023 Dec; 14(12):1619-1620. PubMed ID: 38116425
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
    Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
    Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.
    Zhang C; Chen Y; Li Y; Shi N; Teng Y; Li N; Tang M; Ma Z; Deng D; Chen L
    Eur J Med Chem; 2024 Feb; 265():116076. PubMed ID: 38171150
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel Heterocyclic Compounds for Treating Huntington's Disease.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2024 Mar; 15(3):324-325. PubMed ID: 38505841
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Novel Serine-Arginine Protein Kinase Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 May; 14(5):551-552. PubMed ID: 37197468
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 8-Aza Quinazolines as Brain Penetrant SOS1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Nov; 14(11):1487-1488. PubMed ID: 37974940
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Harnessing Protein-Ligand Interaction Fingerprints to Predict New Scaffolds of RIPK1 Inhibitors.
    Aniceto N; Marques V; Amaral JD; Serra PA; Moreira R; Rodrigues CMP; Guedes RC
    Molecules; 2022 Jul; 27(15):. PubMed ID: 35897894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.